Immunotherapy in the treatment of advanced prostate cancer

Bob Djavan, Kathleen Nelson, Amir Kazzazi, Aron Bruhn, Helen Sadri, Alejandro Gomez-Pinillos, Anna C. Ferrari

Research output: Contribution to journalReview article

2 Scopus citations


Prostate cancer is a complex disease, and treatment selection is informed by numerous variables depending on the stage of disease. Moreover, patient expectations and the impact of treatment-related adverse events may influence treatment choices. Available treatment options over the course of the disease have included surgery, radiation therapy, hormonal therapy, immunotherapy, and chemotherapy. This complexity requires an understanding of a wide range of treatment options and the support of a multidisciplinary team that involves urologists, radiation oncologists, diagnostic radiologists, pathologists, and medical oncologists. Collaboration among these physicians allows for a comprehensive treatment strategy that addresses the individual needs of the patient throughout the course of his disease. Prior to 2004, treatment options for metastatic castrateresistant prostate cancer (CRPC) were limited to therapies for palliation of pain and reduction of skeletalrelated events. Over the past 7 years, four therapeutic options-three within the last 2 years-that provide a survival benefit in this setting have been approved. These therapies have diverse mechanisms, perhaps reflecting the complex nature of advanced prostate cancer. Among them is sipuleucel-T, the first autologous immunotherapy approved for any cancer. This review will discuss the rapidly changing treatment environment for metastatic CRPC and the increased exploration of immunotherapeutic approaches to advanced prostate cancer.

Original languageEnglish (US)
Pages (from-to)5865-5874
Number of pages10
JournalCanadian Journal of Urology
Issue number5
StatePublished - Oct 1 2011

All Science Journal Classification (ASJC) codes

  • Urology


  • Abiraterone
  • Active immunotherapy
  • Advanced prostate cancer
  • Autologous cellular immunotherapy
  • Cabazitaxel
  • Docetaxel
  • GVAX
  • Immunotherapy
  • Ipilimumab
  • Metastatic castrateresistant prostate cancer
  • Sipuleucel-T

Fingerprint Dive into the research topics of 'Immunotherapy in the treatment of advanced prostate cancer'. Together they form a unique fingerprint.

  • Cite this

    Djavan, B., Nelson, K., Kazzazi, A., Bruhn, A., Sadri, H., Gomez-Pinillos, A., & Ferrari, A. C. (2011). Immunotherapy in the treatment of advanced prostate cancer. Canadian Journal of Urology, 18(5), 5865-5874.